Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Anti-VEGF/PDGFR (Vascular Endothelial Growth Factor/Platelet-Derived Growth Factor Receptor) beta double-specificity antibody and application thereof

A bispecific antibody and antibody technology, applied in the direction of antibodies, anti-tumor drugs, hybrid immunoglobulins, etc., can solve the problems of high toxicity and toxicity, achieve good tumor activity, inhibit growth, and avoid the increase of drug dosage Effect

Inactive Publication Date: 2011-11-23
CHANGZHOU ADAM BIOTECH
View PDF3 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, these small molecule inhibitors have certain toxicity to the human body, especially when they are combined with chemotherapy (Sosman et al.2007, Roodhart et al.2008)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-VEGF/PDGFR (Vascular Endothelial Growth Factor/Platelet-Derived Growth Factor Receptor) beta double-specificity antibody and application thereof
  • Anti-VEGF/PDGFR (Vascular Endothelial Growth Factor/Platelet-Derived Growth Factor Receptor) beta double-specificity antibody and application thereof
  • Anti-VEGF/PDGFR (Vascular Endothelial Growth Factor/Platelet-Derived Growth Factor Receptor) beta double-specificity antibody and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0072] 1. Nucleotide sequence design and synthesis of anti-VEGF-PDGFRbeta bispecific antibody (bsAb):

[0073] Such as figure 1 Shown, according to the heavy chain HC of the bsAb VEGF -(GGGGS) 3 -HC PDGFRbeta (Reverse) amino acid sequence and connection form Design heavy chain nucleotide sequence, and add Sac I restriction site, KOZAK sequence and leader sequence at the 5' end of the sequence, and add Xho I restriction site at its 3' end point. Design three oligonucleotide primers containing EcoR I restriction site at the 3' end to synthesize heavy chain HC respectively VEGF -(GGGGS) 3 and HCPDGFRbeta (Reverse) fragment, the full-length 2658bp bsAb heavy chain gene was synthesized by PCR direct ligation method (SDL PCR).

[0074] According to the amino acid sequence of human anti-VEGF-A IgG1 light chain and human anti-PDGFRbeta IgG1 light chain amino acid sequence, the 5' end contains Not I restriction site, KOZAK sequence and leader sequence, and the 3' end contains Psi...

Embodiment 2

[0086] Antigen-antibody binding test (ELISA method):

[0087] 1. Coating: Dilute the antigen (hVEGF-A or PDGFRbeta) to a protein content of 5 μg / ml with 0.05M PH9.1 carbonate coating buffer. Add 0.1ml to the reaction well of each polystyrene plate, overnight at 4°C. The next day, the solution in the well was discarded, and washed 3 times with washing buffer, 3 minutes each time.

[0088] 2. Adding samples: Add 0.1ml of a certain dilution of the antibody to be tested (anti-VEGF Fab, anti-PDGFR beta monoclonal antibody or anti-VEGF-PDGFR beta bsAb) to the above-mentioned coated reaction wells, and incubate at 37°C for 1 Hour. Then wash. (Make blank wells, negative control wells and positive control wells at the same time).

[0089] 3. Add enzyme-labeled antibody (goat anti-human IgG-gamma): Add 0.1 ml of freshly diluted enzyme-labeled antibody (diluted after titration) to each reaction well. Incubate at 37°C for 0.5-1 hour and wash.

[0090] 4. Add substrate solution for c...

Embodiment 3

[0097] Anti-VEGF / PDGFRbeta bispecific anti-human nasopharyngeal carcinoma CNE xenograft tumor growth inhibition test in nude mice

[0098] Take the tumor tissue in the vigorous growth period and cut it into 1.5mm 3 Left and right, under sterile conditions, inoculated subcutaneously on the right side of nude mice. Use a vernier caliper to measure the diameter of the transplanted tumor in mice, and wait until the tumor grows to 100-200mm 3 Animals were then randomly grouped. Using the method of measuring the tumor diameter, dynamically observe the anti-tumor effect of the tested animals. Tumor diameter was measured once every 2 days, and the weight of the mouse was also weighed at the same time as each measurement. The experimental group was injected with anti-VEGF / PDGFRbeta bispecific antibody through the tail vein, once a day, and the negative group was given the same amount of normal saline at the same time. Tumor volume calculation formula:

[0099] TV=0.52×a×b 2

[0...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Tumor inhibition rateaaaaaaaaaa
Tumor inhibition rateaaaaaaaaaa
Tumor inhibition rateaaaaaaaaaa
Login to View More

Abstract

The invention relates to a double-specificity monoclonal antibody medicament, in particular to an anti-vascular endothelial growth factor (VEGF / VEGF-A) and anti-platelet-derived growth factor receptor (PDGFR) double-specificity monoclonal antibody medicament for resisting tumor angiogenesis; and the anti-VEGF / PDGFR beta double-specificity antibody is characterized by being constructed by connecting an anti-PDGFR beta single-chain antibody at the tail end of an FC segment based on an anti-VEGF monoclonal antibody.

Description

technical field [0001] This patent relates to bispecific monoclonal antibody drugs, especially anti-tumor angiogenesis anti-human vascular endothelial growth factor (VEGF / VEGF-A) and human platelet-derived growth factor receptor (PDGFR) bispecific monoclonal antibody drugs ; Background technique [0002] Tumor growth accompanied by neovascularization has been reported in the literature more than a century ago (Ferrara 2002). But it was not until 1939 that Ide and his colleagues proposed for the first time that there may be some tumor-derived angiogenesis stimulator that provides blood vessel supply for tumor growth (Ide et al.1939). Years later, Algire et al. argued that "the rapid spread of tumors depends on a rich vascular supply" (Algire et al. 1945), after observing that increased vascular density preceded rapid tumor growth. In the 1960s, experiments by Greenblatt and Shubik (Greenblatt et al.1968) and Ehrmann and Knoth (Ehrmann et al.1968) successively provided preli...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K16/46A61K39/395A61P35/00
Inventor 霍世元叶亚东滕凌朱文华潘鹂路易斯易格那罗
Owner CHANGZHOU ADAM BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com